WHAT IS CLAIMED IS:

1. A method of determining if a first bacterium having a first genome or a second bacterium having a second genome is present in a test sample or an initial sample from which the test sample was prepared, the method comprising:

(a) probing the test sample with a virtual probe comprising two or more probe molecules, wherein:

(i) the probe molecules of the virtual probe are positionally addressable probe molecules present on an array, each at a discrete location on the array;

(ii) each probe molecule is capable of specifically hybridizing to one or more target nucleic acids corresponding to the first genome and/or one or more homologous target nucleic acids corresponding to the second genome, wherein the one or more target nucleic acids corresponding to the first genome are a first amplicon set and the one or more target nucleic acids corresponding to the second genome are a second amplicon set, wherein the first amplicon set and the second amplicon set each comprise one or more of (A) a nucleotide sequence corresponding to a 16S rRNA gene, (B) a nucleotide sequence corresponding to a 23S rRNA gene, and (C) a nucleotide sequence corresponding to a 16S-23S intergenic spacer region; and

(iii) the probe molecules hybridize non-identically to the amplicons in the first and the second amplicon set, such that the hybridizing of the probe molecules can distinguish between the first amplicon set and the second amplicon set; and

(b) detecting and/or quantifying signals from hybridization of the probe molecules in the virtual probe to nucleic acids, if any, in the test sample,

thereby determining if the first bacterium or second bacterium is present in the test sample or initial sample.

2. The method of claim 1, wherein the first amplicon set and the second amplicon set each comprise a nucleotide sequence corresponding to a 16S rRNA gene.

3. The method of claim 1 or 2, wherein the first amplicon set and the second amplicon set each comprise a nucleotide sequence corresponding to a 23S rRNA gene.

4. The method of any one of claims 1 to 3, wherein the first amplicon set and the second amplicon set each comprise a nucleotide sequence corresponding to a 16S-23S intergenic spacer region.

5. The method of any one of claims 1 to 4, wherein the first amplicon set and the second amplicon set each comprise a nucleotide sequence corresponding to a 16S rRNA gene, a nucleotide sequence corresponding to a 23S rRNA gene, and a nucleotide sequence corresponding to a 16S-23S intergenic spacer region.

6. The method of any one of claims 1 to 5, which further comprises preparing the test sample by performing a PCR amplification reaction on the initial sample using PCR primers capable of hybridizing to, and initiating PCR amplification from, both the first genome and the second genome, resulting in the first amplicon set and the second amplicon set, respectively, when the first genome and second genome are present in the initial sample.

7. The method of claim 6, wherein the PCR primers comprise more than one primer pair and wherein the first amplicon set comprises a plurality of first amplicons and/or the second amplicon set comprises a plurality of second amplicons.

8. The method of claim 6, wherein the PCR primers comprise a single primer pair and the first amplicon set consists of a single first amplicon and the second amplicon set consists of a single second amplicon.

9. The method of any one of claims 1 to 8, wherein the first bacterium is a coagulase negative *Staphylococcus sp*. and the second bacterium is a coagulase positive *Staphylococcus sp*.

10. The method of claim 9, wherein the second bacterium is *S. aureus*.

11. The method of claim 9 or 10, wherein the virtual probe comprises a first probe molecule having a nucleotide sequence comprising CCAGTCTTATAGGTAGGTTAYCCACG (SEQ ID NO:1) and a second probe molecule having a nucleotide sequence comprising GCTTCTCGTCCGTTCGCTCG (SEQ ID NO:2).

12. The method of any one of claims 1 to 8, wherein the first bacterium is *Streptococcus gordonii* and the second bacterium is *Streptococcus anginosus*.

13. The method of claim 12, wherein the virtual probe comprises a first probe molecule having a nucleotide sequence comprising CAGTCTATGGTGTAGCAAGCTACGGTAT (SEQ ID NO:3) and a second probe molecule having a nucleotide sequence comprising TATCCCCCTCTAATAGGCAGGTTA (SEQ ID NO:4).

14. The method of any one of claims 1 to 8, wherein the first bacterium is *Streptococcus mitis* and the second bacterium is *Streptococcus pneumoniae*.

15. The method of claim 14, wherein the virtual probe comprises a first probe molecule having a nucleotide sequence comprising GATGCAAGTGCACCTTTTAAGTAA (SEQ ID NO:7 and a second probe molecule having a nucleotide sequence comprising AGCTAATACAACGCAGGTCCATCT (SEQ ID NO:5).

16. The method of claim 14, wherein the virtual probe comprises a first probe molecule having a nucleotide sequence comprising GATGCAAGTGCACCTTTTAAGCAA (SEQ ID NO:6), a second probe molecule having a nucleotide sequence comprising GATGCAAGTGCACCTTTTAAGTAA (SEQ ID NO:7) and a third probe molecule having a nucleotide sequence comprising AGCTAATACAACGCAGGTCCATCT (SEQ ID NO:5).

17. The method of any one of claims 1 to 8, wherein the first and the second bacteria are *Enterobacteriaceae* bacteria.

18. The method of claim 17, wherein the first and second bacteria are selected from *Enterobacter aerogenes, Enterobacter asburiae*, and *Enterobacter hormaechei.*

19. The method of any one of claims 1 to 18, wherein the initial sample is a blood sample.

20. An addressable array, comprising:

(a) one or more virtual probes for distinguishing a first genomic sequence from a second homologous genomic sequence, each virtual probe comprising a group of positionally addressable oligonucleotide probe molecules, each at a discrete location on the array, wherein each probe molecule in the one or more virtual probes comprises a nucleotide sequence that is 90% to 100% complementary to 15 to 40 consecutive nucleotides in the first genomic sequence or the second genomic sequence; and

(b) optionally, one or more control probe molecules.

21. The addressable array of claim 20, in which at least one virtual probe comprises a probe molecule whose nucleotide sequence comprises CCAGTCTTATAGGTAGGTTAYCCACG (SEQ ID NO:1), GCTTCTCGTCCGTTCGCTCG (SEQ ID NO:2), CAGTCTATGGTGTAGCAAGCTACGGTAT (SEQ ID NO:3), TATCCCCCTCTAATAGGCAGGTTA (SEQ ID NO:4), AGCTAATACAACGCAGGTCCATCT (SEQ ID NO:5), GATGCAAGTGCACCTTTTAAGCAA (SEQ ID NO:6), or GATGCAAGTGCACCTTTTAAGTAA (SEQ ID NO:7).

22. An oligonucleotide probe molecule whose nucleotide sequence comprises CCAGTCTTATAGGTAGGTTAYCCACG (SEQ ID NO:1), GCTTCTCGTCCGTTCGCTCG (SEQ ID NO:2), CAGTCTATGGTGTAGCAAGCTACGGTAT (SEQ ID NO:3), TATCCCCCTCTAATAGGCAGGTTA (SEQ ID NO:4), AGCTAATACAACGCAGGTCCATCT (SEQ ID NO:5), GATGCAAGTGCACCTTTTAAGCAA (SEQ ID NO:6), or GATGCAAGTGCACCTTTTAAGTAA (SEQ ID NO:7).

23. A virtual probe comprising a plurality of oligonucleotide probe molecules, wherein:

(a) at least one oligonucleotide probe molecule in the virtual probe has a nucleotide sequence comprising CCAGTCTTATAGGTAGGTTAYCCACG (SEQ ID NO:1) and another oligonucleotide molecule in the virtual probe has a nucleotide sequence comprising GCTTCTCGTCCGTTCGCTCG (SEQ ID NO:2);

(b) at least one oligonucleotide probe molecule in the virtual probe has a nucleotide sequence comprising CAGTCTATGGTGTAGCAAGCTACGGTAT (SEQ ID NO:3) and another oligonucleotide molecule in the virtual probe has a nucleotide sequence comprising TATCCCCCTCTAATAGGCAGGTTA (SEQ ID NO:4); or

(c) at least one oligonucleotide probe molecule in the virtual probe has a nucleotide sequence comprising AGCTAATACAACGCAGGTCCATCT (SEQ ID NO:5), another oligonucleotide molecule in the virtual probe has a nucleotide sequence comprising GATGCAAGTGCACCTTTTAAGCAA (SEQ ID NO:6) and another oligonucleotide molecule in the virtual probe has a nucleotide sequence comprising GATGCAAGTGCACCTTTTAAGTAA (SEQ ID NO:7).

24. An addressable array comprising a group of positionally addressable probe molecules, each at a discrete location on the array, wherein the group of probe molecules comprises the oligonucleotide probe molecule of claim 22.

25. An addressable array comprising the virtual probe of claim 23, wherein each probe molecule in the virtual probe is at a discrete location on the array.

26. A system for determining if an organism is present in a sample, comprising:

(a) an optical reader for generating signal data for each probe molecule location of the array of claim 20 or claim 21; and

(b) at least one processor which:

(i) is configured to receive signal data from the optical reader;

(ii) is configured to analyze the signal data for the one or more virtual probes; and

(iii) has an interface to a storage or display device or network for outputting a result of the analysis.